STAR

March 19 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• STRIDES PHARMA SCIENCE - CO, ARCO LAB APPROVE DEMERGER OF IDENTIFIED BUSINESS OF ARCO LAB

Source text: ID:nNSEbkyWGB

Further company coverage: SRID.NS

(([email protected];))

March 14 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• STRIDES PHARMA SCIENCE LTD - UNIT PROPOSED TO ACQUIRE 100% STAKE IN AMEXEL PTE. LTD.

• STRIDES PHARMA SCIENCE LTD - UNIT PROPOSES TO CREATE BUSINESS PLATFORM IN SOUTHEAST ASIA

Source text: ID:nBSE5Grkf4

Further company coverage: SRID.NS

(([email protected];))

** Shares of Indian Pharma companies which make drugs for HIV rise between 2% to 13%

** U.S. decides to resume funding HIV treatment after pausing the foreign aid on Jan. 26

** Strides Pharma SRID.NS up 13%, Laurus Labs LAUL.NS rise 8%, Aurobindo Pharma ARBN.NS rise 3% and Cipla CIPL.NS up 2%

** Strides, which reported 77% rise in Q3 profit earlier in the day, is top gainer on the pharma index .NIPHARM which is up 1%

** Since Jan. 26, LAUL down 10% and SRID fell 5% as of last close, while SRID was largely flat and Cipla was up 1%

(Reporting by Nishit Navin)

(([email protected];))

Jan 20 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• STRIDES PHARMA SCIENCE LTD - RECEIVES USFDA APPROVAL FOR ACETAMINOPHEN AND IBUPROFEN TABLETS

• STRIDES PHARMA SCIENCE LTD - APPROVAL WILL ENHANCE STRIDES' OTC PRODUCT PORTFOLIO

Source text: ID:nBSEbPMJqh

Further company coverage: SRID.NS

(([email protected];;))

Nov 19 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• RECEIPT OF NCLT APPROVAL FOR CREATION OF ONESOURCE

• FOLLOWING APPROVAL, ONESOURCE WILL ADVANCE TOWARDS LISTING ITS SHARES

Source text: ID:nNSE69gFWY

Further company coverage: SRID.NS

(([email protected];;))

Oct 25 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• UNIT SPG ACQUIRES REMAINING STAKE IN STRIDES SWITZERLAND FOR CHF 1.01 MILLION

Source text for Eikon: ID:nBSE3YQjWM

Further company coverage: SRID.NS

(([email protected];))

** Shares of Strides Pharma Science SRID.NS rise 2.5% to 1,599.5 rupees

** The pharma co posted a consolidated net profit of 932.3 mln rupees ($11 mln) vs a loss of 1.31 bln rupees a year ago

** Rev from ops rose 20% Y/Y

** More than 385,000 shares change hands, 1.1x its 30 day avg

** Stock has surged over two-fold so far this year

($1 = 84.0510 Indian rupees)

(Reporting by Ashna Teresa Britto in Bengaluru)

(([email protected] ; ( +91 8078332441))

Oct 16 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• ONESOURCE RECEIVES EQUITY COMMITMENTS OF 8.01 BILLION RUPEES

• COMMITMENTS FROM MARQUEE INVESTORS AT PRE-MONEY EQUITY VALUATION OF $1.65 BILLION

Source text for Eikon: ID:nBSE7MJ6X7

Further company coverage: SRID.NS

(([email protected];;))

Sept 17 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• RBI HAS LEVIED COMPOUNDING AMOUNT OF 15.1 MILLION RUPEES ON COMPANY

• ORDER IN MATTER OF GRANT OF STOCK OPTONS TO NONRESIDENT EMPLOYEE

Further company coverage: SRID.NS

(([email protected];))

Sept 16 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• STRIDES PHARMA SCIENCE LTD - RECEIVES USFDA APPROVAL FOR FLUOXETINE TABS 60 MG

Source text for Eikon: ID:nBSEf6hKM

Further company coverage: SRID.NS

(([email protected];))

Sept 6 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• STRIDES PHARMA SCIENCE LTD - GETS USFDA APPROVAL FOR THEOPHYLLINE EXTENDED-RELEASE TABLET

Source text for Eikon: ID:nBSE3w42Yc

Further company coverage: SRID.NS

(([email protected];))

July 29 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• INDIA’S STRIDES PHARMA SCIENCE JUNE-QUARTER CONSOL NET PROFIT 702 MILLION

• STRIDES PHARMA SCIENCE JUNE-QUARTER CONSOL REVENUE FROM CONTINUING OPERATIONS 10.88 BILLION RUPEES

Source text for Eikon: [ID:]

Further company coverage: SRID.NS

(([email protected];))

** Shares of Strides Pharma Science SRID.NS up 7.8% at 911.75 rupees after rising as much as 8.7% earlier

** Pharmaceutical co reports Q4 consolidated net profit at 181.8 mln rupees ($2.2 mln) vs loss of 95.4 mln rupees yr ago

** Rev from ops rose 9.9% Y/Y

** Stock is witnessing its most active trading session since Feb. 14, with more than 1.6 mln shares changing hands, 5.8x of 30-day avg

** Co sees continuing business revenue to grow at 12-15% Y/Y for FY25

** Says its U.S. business revenue to be in $285 mln-$300 mln range for FY25

** Stock rose ~21% in March quarter, its fourth straight quarterly rise

($1 = 83.2502 Indian rupees)

(Reporting by Ashish Chandra in Bengaluru)

(([email protected] (+91 7982114624))

** Shares of Strides Pharma Science SRID.NS are up around 2%

** SRID gets US FDA approval for Sevelamer Carbonate tablets, used to manage elevated phosphate levels in blood of patients with chronic kidney disease

** Stock is set to post its worst week since early Jan, down 4% for the week

** SRID up 31% YTD vs a 11% rise in Nifty Pharma Index .NIPHARM

(Reporting by Nishit Navin)

(([email protected];))

April 9 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• STRIDES RECEIVES USFDA APPROVAL FOR FLUOXETINE TABS 10 MG AND 20 MG

Source text for Eikon: ID:nBSE6GNL4V

Further company coverage: SRID.NS

(([email protected];))

March 29 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• STRIDES PHARMA SCIENCE LTD - PROPOSES TO CONSOLIDATE GROUP'S SOUTH AFRICAN BUSINESS UNDER TRINITY PHARMA (PROPRIETARY) LIMITED, SOUTH AFRICA

Source text for Eikon: ID:nBSE15mLyg

Further company coverage: SRID.NS

(([email protected];;))

March 28 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• CORPORATE INSOLVENCY RESOLUTION PROCESS AGAINST STRIDES ALATHUR STANDS STAYED BY APPELLATE TRIBUNAL

Source text for Eikon: ID:nBSE7qH1Gm

Further company coverage: SRID.NS

(([email protected];))

** Shares of Strides Pharma Science SRID.NS up 2.3%

** Stock roses as much as 4.8% to day's high of 834.6 rupees

** Pharmaceutical co's unit received U.S. FDA approval for Gabapentin Tablets USP, 600 mg and 800 mg

** It is a commonly used medication for the treatment of neuropathic pain caused by diabetic neuropathy, postherpetic neuralgia, and central pain

** The product is bioequivalent to the reference-listed drug Neurontin Tablets, 600 mg and 800 mg, from Viatris Specialty LLC, co added

** The drug will be manufactured at Strides' Puducherry facility

** Stock is up 25.4% so far this year; after rising 85.6% in 2023

(Reporting by Navamya Ganesh Acharya in Bengaluru)

(([email protected]; +91 8805175330 ;))

Jan 30 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• INDIA’S STRIDES PHARMA SCIENCE DEC-QUARTER CONSOL NET PROFIT 496.7 MILLION RUPEES VERSUS LOSS 800.3 MILLION RUPEES

• STRIDES PHARMA SCIENCE DEC-QUARTER CONSOL REVENUE FROM CONTINUING OPERATIONS 10.38 BILLION RUPEES VERSUS 8.65 BILLION RUPEES

Source text for Eikon: ID:nBSE2NPxSM

Further company coverage: SRID.NS

(([email protected];))

Jan 11 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• UNIT ENTERED INTO A SHARE PURCHASE AGREEMENT FOR DIVESTMENT OF 100% SHAREHOLDING IN ERIS PHARMA GMBH, GERMANY

• DEAL FOR EURO 200,000

Source text for Eikon: ID:nBSE3vsMl7

Further company coverage: SRID.NS

(([email protected];))

Jan 5 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• STRIDES PHARMA SCIENCE LTD - UNIT ACQUIRED ADDITIONAL STAKE IN NEVITON SOFTECH

Source text for Eikon: ID:nBSEb0zDJ7

Further company coverage: SRID.NS

(([email protected];;))

Dec 21 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• UNIT AVAILED CREDIT FACILITY FROM A DIVISION OF INVESTEC BANK, SOUTH AFRICA

• UNIT AVAILED CREDIT FACILITY FOR THEIR WORKING CAPITAL REQUIREMENTS

Further company coverage: SRID.NS

(([email protected];))

Dec 1 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• LAUNCHES ICOSAPENT ETHYL ACID SOFT GEL CAPSULES IN PARTNERSHIP WITH AMNEAL

Source text for Eikon: [ID:]

Further company coverage: SRID.NS

(([email protected];))

Nov 23 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• STRIDES PHARMA SCIENCE LTD- RECEIVES USFDA APPROVAL FOR GENERIC SUPREP BOWEL PREP KIT

Source text for Eikon: ID:nNSE50tqjt

Further company coverage: SRID.NS

(([email protected];))

Nov 21 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• STRIDES RECEIVES USFDA APPROVAL FOR LEVETIRACETAM ORAL SOLUTION

Source text for Eikon: ID:nNSEhvMXW

Further company coverage: SRID.NS

(([email protected];;))

Oct 30 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• INDIA'S STRIDES PHARMA SCIENCE LTD SEPT-QUARTER CONSOL NET LOSS 1.31 BILLION RUPEES VERSUS PROFIT 228.3 MILLION RUPEES

• STRIDES PHARMA SCIENCE LTD SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 9.99 BILLION RUPEES VERSUS 8.97 BILLION RUPEES

Source text for Eikon: ID:nBSEcdSc3w

Further company coverage: SRID.NS

(([email protected];))

Oct 27 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• STRIDES ANNOUNCES SALE OF MANUFACTURING FACILITY IN SINGAPORE FOR CONSIDERATION OF $15 MILLION

Source text for Eikon: ID:nBSE92RnVw

Further company coverage: SRID.NS

(([email protected];))

** Shares of Strides Pharma Science SRID.NS rise as much as 4.17% to 516.80 rupees apiece

** Drugmaker reaffirms its EBITDA guidance in the range of 7 bln rupees and 7.50 bln rupees for FY24

** Adds, decision to spin off contract development and manufacturing organisation (CDMO) and soft gelatin business will unlock value for shareholders

** SRID's unit also receives U.S. FDA approval for icosapent ethyl capsules, used to treat patients with hypertriglyceridemia

** Drug has a market size of $1.3 billion in the U.S.: SRID

** SRID's shares up 46% in 2023 so far including day's gains, compared to 20% rise in pharma index .NIPHARM - LSEG data

(Reporting by Bharath Rajeswaran in Bengaluru)

(([email protected]; +91 9769003463))

Oct 3 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• STRIDES PHARMA SCIENCE LTD - RECEIVES USFDA APPROVAL FOR ICOSAPENT ETHYL CAPSULES

Source text for Eikon: ID:nBSECFKMz

Further company coverage: SRID.NS

(([email protected];))

** Shares of Strides Pharma Science SRID.NS fall as much as 3.3% to 518.1 rupees, biggest pct fall since Sept 12

** Co on Monday said it would spin off its contract development and manufacturing organisation (CDMO) and soft gelatin business into a new entity named "OneSource"

** Shareholders of Strides will receive one share of OneSource for every two shares held in Strides

** Co's shares valued at 364 rupees, a 32.1% discount to last close of 535.9 rupees

** More than 1.4 mln shares change hands by 11:30 a.m. IST vs 1.8x 30-day avg of 768,800 shares

** Including session's loss, stock up ~52% YTD

(Reporting by Ashna Teresa Britto in Bengaluru)

(([email protected] ; ( +91 8078332441))